Abstract 766P
Background
Glioblastoma (GBM) is a disease with high mortality reported worldwide. Stupp protocol is a common option to pts with GBM. Surufatinib (SUR) is a TKI which demonstrated encouraging efficacy in neuroendocrine tumors and other cancers. We conducted this study to evaluate the efficacy and safety of a modified stupp protocol with SUR.
Methods
The main eligibility criteria included radiographically or histologically proven GBM, age between 18 and 75 years, an Eastern Cooperative Oncology Group performance status (ECOG PS) less than 2, and a Karnofsky performance scales (KPS) no less than 60. The pts would receive radiotherapy at a dose of 2 Gy per day 5 times in a week for 6 weeks, orally concurrent temozolomide (TMZ) 75mg/m2 daily for up to 7 weeks, and intravenously bevacizumab (BEV) 7.5mg/kg every 21 days for up to 3 times. For adjuvant treatment, the pts would receive orally TMZ 150 (escalated to 200 if no AE with grade greater than 2 occurred) mg/m2 on day 1 to day 5 weekly and orally BEV on day 1 and day 15 in 28-day cycles for 12 weeks, and afterwards orally SUR 150/200 mg as appropriate daily until intolerable toxicity or progressive disease. The primary endpoint was progression-free survival (PFS).
Results
From Dec 8, 2021 to Jul 8, 2024, 40 pts were enrolled. IDH mutation detection was performed in 21 pts, and 12 pts were IDH mutant. Ki-67 immunohistochemistry was performed in 30 pts, and 12 pts had a ki-67 index no less than 30. With a median follow-up of 5.13 months, the median PFS was 7 (95% CI: 4-8) months. The 3-month, 6-month, 9-month, and 12-month PFS rate was 79.49 (95% CI: 66.81-92.16) %, 51.28 (95% CI: 35.59-66.97) %, 20.51 (95% CI: 7.84-33.19) %, and 12.82 (95% CI: 2.33-23.31) %, respectively. No pts died during the following-up. 39 pts had at least one post-baseline tumor assessment. One patient achieved CR, 10 pts achieved PR, 8 patients had stable disease, and 20 pts experienced progressive disease. The ORR was 28.21% (11/39), and the DCR was 48.72% (19/39).
Conclusions
The modified STUPP protocol followed by surufatinib as maintenance therapy demonstrated promising outcomes in GBM, which warrants further explorations.
Clinical trial identification
Editorial acknowledgement
The authors thank all the patients involved in this study. We also thank Chao Zhao and Zheng Wang from HUTCHMED for the assistance in data analysis and writing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.